viruses

In his weekly clinical update Dr. Griffin discusses Influenza incidence and vaccine effectiveness during the southern hemisphere influenza season in Chile, Nirsevimab for prevention of RSV infection in healthy late-preterm and term infants, severe Monkeypox in hospitalized patients, reinfections with different SARS-CoV-2 Omicron subvariants, impact of community masking on COVID-19 in Bangladesh, unadjuvanted intranasal spike vaccine elicits protective …

TWiV 951: Clinical update with Dr. Daniel Griffin Read More »

In his weekly clinical update Dr. Griffin discusses progress toward poliomyelitis eradication in Pakistan, polio by the numbers , influenza and COVID-19 vaccination coverage among health care personnel, phase 1/2a safety and immunogenicity of an adenovirus 26 vector RSV vaccine encoding prefusion F in adults 18–50 years and RSV seropositive children 12–24 months, receipt of first and second doses of JYNNEOS vaccine for prevention of Monkeypox, distinguishing SARS-CoV-2 persistence and reinfection, Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages, association between regular physical activity and the protective effect of vaccination against SARS-CoV-2 in a South African case, COVID-19 outcomes in solid organ transplant recipients who received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab treatment, Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralizing antibodies, and Tocilizumab versus Baricitinib in hospitalized patients with severe COVID-19.

In his weekly clinical update Dr. Griffin discusses the prediction of upcoming global infection burden of influenza seasons after relaxation of public health and social measures during the COVID-19 pandemic, severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters, and how successful immunomodulators for treatment of COVID-19 have opened the pathway for comparative trials.

In his weekly clinical update Dr. Griffin discusses a healthcare-associated infection with Monkeypox virus, air and surface sampling for monkeypox virus in a UK hospital, misrepresentation and nonadherence regarding COVID19 public health measures, tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine, clinical, virologic, and immunologic evaluation of symptomatic rebound following Nirmatrelvir/Ritonavir treatment, early outpatient treatment with Eemdesivir in patients at high risk for severe COVID-19, Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes, and outcomes among confirmed cases and a matched comparison group in the long-COVID in Scotland.